Highview Capital Management LLC DE grew its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 6,763 shares of the company’s stock after buying an additional 181 shares during the quarter. Eli Lilly and Company makes up about 2.4% of Highview Capital Management LLC DE’s investment portfolio, making the stock its 10th largest holding. Highview Capital Management LLC DE’s holdings in Eli Lilly and Company were worth $5,992,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also bought and sold shares of the business. Twelve Points Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 1.4% during the second quarter. Twelve Points Wealth Management LLC now owns 811 shares of the company’s stock valued at $734,000 after buying an additional 11 shares during the last quarter. Verum Partners LLC grew its stake in Eli Lilly and Company by 1.5% in the second quarter. Verum Partners LLC now owns 731 shares of the company’s stock worth $662,000 after purchasing an additional 11 shares in the last quarter. Beaird Harris Wealth Management LLC grew its stake in Eli Lilly and Company by 2.2% in the second quarter. Beaird Harris Wealth Management LLC now owns 512 shares of the company’s stock worth $464,000 after purchasing an additional 11 shares in the last quarter. Summit Financial Strategies Inc. grew its stake in Eli Lilly and Company by 0.5% in the third quarter. Summit Financial Strategies Inc. now owns 2,105 shares of the company’s stock worth $1,865,000 after purchasing an additional 11 shares in the last quarter. Finally, Prio Wealth Limited Partnership grew its stake in Eli Lilly and Company by 0.5% in the third quarter. Prio Wealth Limited Partnership now owns 2,411 shares of the company’s stock worth $2,136,000 after purchasing an additional 11 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages recently issued reports on LLY. Guggenheim increased their price objective on Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Bank of America increased their price objective on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. BMO Capital Markets increased their price objective on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Wells Fargo & Company upped their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Finally, Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a report on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,013.41.
Eli Lilly and Company Stock Performance
Shares of LLY stock opened at $846.90 on Thursday. The firm has a market capitalization of $804.90 billion, a price-to-earnings ratio of 124.73, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The business has a fifty day moving average of $916.20 and a 200 day moving average of $865.10. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.53 by ($0.35). The firm had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business’s revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the business earned $0.10 EPS. As a group, research analysts expect that Eli Lilly and Company will post 14.05 earnings per share for the current year.
Eli Lilly and Company Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.61%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- How is Compound Interest Calculated?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Stock Market Upgrades: What Are They?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- The Most Important Warren Buffett Stock for Investors: His Own
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.